An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)


  • Org Study ID: D910FC00001
  • Secondary ID: N/A
  • NCT ID: NCT04078152
  • Sponsor: AstraZeneca


The aims of the study are to monitor the long-term safety of durvalumab, to provide continued treatment or retreatment with durvalumab to eligible patients, and to collect overall survival (OS) information.


This is a multicenter, open-label, global study that will enroll patients who are currently receiving durvalumab monotherapy, or have previously received durvalumab as monotherapy or in combination with any other approved or investigational anticancer agents, in an eligible AstraZeneca/MedImmune-sponsored clinical study.

  • Overall Status
    Active, not recruiting
  • Start Date
    September 5, 2019
  • Phase
    Phase 4
  • Study Type


Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A


  • Solid Tumor


Inclusion Criteria:
1. Patient must be 18 years or older, at the time of signing the ICF. For subjects aged < 20 years and enrolled in Japan, a written ICF should be obtained from the subject and his or her legally acceptable representative. - 2. Patient received durvalumab monotherapy and/or durvalumab containing combination in an AstraZeneca/MedImmune-sponsored parent clinical study that is approved for enrollment into this study. - 3. Patients who received durvalumab in combination with any other approved or investigational anticancer agents in the parent clinical study must have completed or discontinued all other anticancer therapy (beyond durvalumab regimen). - 4. Patient must be willing and able to provide written informed consent and to comply with scheduled visits and other study procedures.
Exclusion Criteria:
The following exclusion criteria apply only to patients receiving treatment or retreatment:
1. Currently receiving treatment in another interventional study other than the parent clinical study or, for retreatment patients, received treatment during the follow up period with an agent other than durvalumab

- 2. Any concurrent chemotherapy, IP, biologic or hormonal therapy for cancer treatment

- 3. Experienced an immune-mediated or non-immune-mediated toxicity that led to permanent discontinuation of durvalumab in parent clinical study

- 4. Diagnosis of a new primary malignancy since enrollment into the parent clinical study

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No


Name: Jared Weiss, MD

Role: Principal Investigator

Affiliation: University of North Carolina, Chapel Hill

Overall Contact

Name: N/A

Phone: N/A

Email: N/A


Facility Status Contact